Anderson Michele A.
Chief Development Officer
Anderson Michele A. has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Aug 7, 2026.
On the most recent filing, Anderson Michele A. is listed as Chief Development Officer at Braveheart Bio, Inc. Inside the rolling window, Anderson Michele A. reported 1 open-market purchase totaling $20K in BRVE and no open-market sales.
Companies traded
Other insiders at BRVE
Insider Buying
$20K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Anderson Michele A. made?
Anderson Michele A. has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Anderson Michele A. trade?
Anderson Michele A. has filed SEC Form 4 disclosures for 1 company, including BRVE.
When was Anderson Michele A.'s most recent SEC Form 4 filing?
Anderson Michele A.'s most recent SEC Form 4 filing on Tracefour is dated Aug 7, 2026.
What is Anderson Michele A.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Anderson Michele A. is listed as Chief Development Officer.
What is Anderson Michele A.'s total buy and sell value in the current window?
Inside the rolling retention window, Anderson Michele A. bought $20K and sold $0 based on SEC Form 4 filings.
What was Anderson Michele A.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 1,111 BRVE shares on 2026-08-07, worth $20K, per SEC Form 4 filings.